Clinical trial · no report yet · Phase 3

ULTRAS trial: what clinicians have said so far

Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

NCT06362395 ↗
Recruiting
University Health Network, Toronto
Focused size, estimated: 1–150 verified statements once built

We haven't built an HCP commentary report on ULTRAS (liver metastases; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on ULTRAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
9 posts on X, typically up to 40 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction
Phase: Phase 3
Status: Recruiting
Conditions: Liver Metastases
Interventions: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Arms: MRL adaptive high dose · Experimental
MRL adaptive ultra-high dose · Other
Enrollment: 114 (estimated)
Primary outcomes: Local control (LC) of treated target lesion compared to high dose MR-guided stereotactic single-fraction radiation.
Sponsor: University Health Network, Toronto
Start: Dec 5, 2024
Primary completion: Sep 2031 (estimated)
Results posted: No
Registry record: NCT06362395 · updated Mar 4, 2026

Publications

linked from the registry

Wong H, Ng SSW, Mohamad I, Alborz J, Stanescu T, Liu ZA, De Leon J, Tan H, Ng SP, Radhakrishna G, Bahij R, Intven M, Kirichenko A, Mesci A, Yan M, Dawson L, Augilera T, Hosni A. Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial. Contemp Clin Trials. 2026 Aug;167:108381. doi: 10.1016/j.cct.2026.108381. Epub 2026 Jun 17. PubMed 42309387

Get this report

Focused

Report, built on orderBuilt within 24 hours of confirming your order: $750

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md